Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid 1

Interventions

venetoclax 6Azacitidine 6Cytarabine 5fludarabine 4Methotrexate 3fludarabine phosphate 2aldesleukin 2RO6839921 2Mitoxantrone 2Interleukin-2 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Decitabine 2Dasatinib 2zileuton 1thymoglobulin 1spartalizumab 1sabatolimab 1quizartinib 1pulrodemstat besilate 1posaconazole 1plerixafor 1gilteritinib 1etoposide phosphate 1emvododstat 1daratumumab 1blinatumomab 1Sorafenib 1Sirolimus 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid × AVE9633 × Clear all
NCT00543972 2009-05-14

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Sanofi

Phase 1 Terminated
12 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡